Skip to main content

Advertisement

SpringerLink
Log in

Adjuvant Chemotherapy Improves Overall Survival of Rectal Cancer Patients Treated with Neoadjuvant Chemoradiotherapy Regardless of Pathologic Nodal Status

  • Colorectal Cancer
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Background

After neoadjuvant chemoradiotherapy for rectal cancer, the interpretation of surgical pathology poses difficulties in deciding the need for adjuvant chemotherapy (AC). The aim of this study was to determine whether there is a survival benefit to providing AC in patients with node-negative disease on surgical pathology.

Methods

Patients with clinical stage II and III rectal adenocarcinoma who received neoadjuvant chemoradiation and definitive surgical resection from 2006 to 2012 were identified in the National Cancer Data Base. Patients were stratified by both receipt of AC and nodal status on surgical pathology. Propensity score matching was used to form two cohorts (AC vs. no AC) with otherwise balanced characteristics. Overall survival was compared by Kaplan–Meier analysis, and multivariable survival analysis was performed by a Weibull model.

Results

After propensity score matching, 4172 patients who received adjuvant therapy (2645 node negative and 1527 node positive) and 4172 patients who did not receive adjuvant therapy (3063 node negative and 1109 node positive) were identified. Among patients with either node-negative or node-positive disease, the use of AC was associated with a significant improvement in overall survival. These results were also observed after using a multivariable survival model to control for clinical stage as well as patient- and facility-related characteristics.

Conclusions

In both patients with node-negative and node-positive disease on surgical pathology, the use of AC is associated with a survival benefit. In the absence of contraindications, AC should continue to be routinely recommended to patients after neoadjuvant chemoradiotherapy for locally advanced rectal cancers.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Boyle P, Ferlay J. Mortality and survival in breast and colorectal cancer. Nat Clin Pract Oncol. 2005;2:424–5.

    Article  PubMed  Google Scholar 

  2. Jemal A, Clegg LX, Ward E, et al. Annual report to the nation on the status of cancer, 1975–2001, with a special feature regarding survival. Cancer. 2004;101:3–27.

    Article  PubMed  Google Scholar 

  3. Quah HM, Chou JF, Gonen M, et al. Pathologic stage is most prognostic of disease-free survival in locally advanced rectal cancer patients after preoperative chemoradiation. Cancer. 2008;113:57–64.

    Article  PubMed  Google Scholar 

  4. Bufalari A, Boselli C, Giustozzi G, et al. Locally advanced rectal cancer: a multivariate analysis of outcome risk factors. J Surg Oncol. 2000;74:2–10.

    Article  CAS  PubMed  Google Scholar 

  5. Sauer R, Becker H, Hohenberger W, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004;351:1731–40.

    Article  CAS  PubMed  Google Scholar 

  6. van Gijn W, Marijnen CA, Nagtegaal ID, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer:12-year follow-up of the multicentre, randomised controlled TME trial. Lancet Oncol. 2011;12:575–82.

    Article  PubMed  Google Scholar 

  7. Pahlman L, Glimelius B Improved survival with preoperative radiotherapy in esectable rectal cancer. Swedish Rectal Cancer Trial. N Engl J Med. 1997;336:980–7.

    Article  Google Scholar 

  8. Folkesson J, Birgisson H, Pahlman L, et al. Swedish Rectal Cancer Trial: long lasting benefits from radiotherapy on survival and local recurrence rate. J Clin Oncol. 2005;23:5644–50.

    Article  PubMed  Google Scholar 

  9. National Comprehensive Cancer Network. Rectal cancer (version 2.2016). 2016. https://www.nccn.org/professionals/physician_gls/pdf/rectal.pdf.

  10. Glimelius B, Tiret E, Cervantes A, et al. Rectal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24(Suppl 6):vi81–8.

    Article  PubMed  Google Scholar 

  11. Janjan NA, Crane C, Feig BW, et al. Improved overall survival among responders to preoperative chemoradiation for locally advanced rectal cancer. Am J Clin Oncol. 2001;24:107–12.

    Article  CAS  PubMed  Google Scholar 

  12. Langman G, Patel A, Bowley DM. Size and distribution of lymph nodes in rectal cancer resection specimens. Dis Colon Rectum. 2015;58:406–14.

    Article  PubMed  Google Scholar 

  13. Leuven E, Sianesi B. psmatch2: Stata module to perform full Mahalanobis and propensity score matching, common support graphing, and covariate imbalance testing. 2003. http://ideas.repec.org/c/boc/bocode/s432001.html.

  14. Glynne-Jones R, Counsell N, Quirke P, et al. Chronicle: results of a randomised phase III trial in locally advanced rectal cancer after neoadjuvant chemoradiation randomising postoperative adjuvant capecitabine plus oxaliplatin (XELOX) versus control. Ann Oncol. 2014;25:1356–62.

    Article  CAS  PubMed  Google Scholar 

  15. Breugom AJ, van Gijn W, Muller EW, et al. Adjuvant chemotherapy for rectal cancer patients treated with preoperative (chemo)radiotherapy and total mesorectal excision: a Dutch Colorectal Cancer Group (DCCG) randomized phase III trial. Ann Oncol. 2015;26:696–701.

    Article  CAS  PubMed  Google Scholar 

  16. Sainato A, Cernusco Luna Nunzia V, Valentini V, et al. No benefit of adjuvant fluorouracil leucovorin chemotherapy after neoadjuvant chemoradiotherapy in locally advanced cancer of the rectum (LARC): long term results of a randomized trial (I-CNR-RT). Radiother Oncol. 2014;113:223–9.

    Article  PubMed  Google Scholar 

  17. Cionini L, Sainato A, De Paoli A, et al. Final results of randomized trial on adjuvant chemotherapy after preoperative chemoradiation in rectal cancer. Radiother Oncol. 2010;96(Suppl 1):S112–4.

    Google Scholar 

  18. Gao P, Song YX, Sun JX, et al. Which is the best postoperative chemotherapy regimen in patients with rectal cancer after neoadjuvant therapy? BMC Cancer. 2014;14:888.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Collette L, Bosset JF, den Dulk M, et al. Patients with curative resection of cT3–4 rectal cancer after preoperative radiotherapy or radiochemotherapy: does anybody benefit from adjuvant fluorouracil-based chemotherapy? A trial of the European Organisation for Research and Treatment of Cancer Radiation Oncology Group. J Clin Oncol. 2007;25:4379–86.

    Article  CAS  PubMed  Google Scholar 

  20. Bosset JF, Calais G, Mineur L, et al. Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study. Lancet Oncol. 2014;15:184–90.

    Article  CAS  PubMed  Google Scholar 

  21. Breugom AJ, Swets M, Bosset JF, et al. Adjuvant chemotherapy after preoperative (chemo)radiotherapy and surgery for patients with rectal cancer: a systematic review and meta-analysis of individual patient data. Lancet Oncol. 2015;16:200–7.

    Article  CAS  PubMed  Google Scholar 

  22. Petrelli F, Coinu A, Lonati V, et al. A systematic review and meta-analysis of adjuvant chemotherapy after neoadjuvant treatment and surgery for rectal cancer. Int J Colorectal Dis. 2015;30:447–57.

    Article  PubMed  Google Scholar 

  23. Petersen SH, Harling H, Kirkeby LT, et al. Postoperative adjuvant chemotherapy in rectal cancer operated for cure. Cochrane Database Syst Rev. 2012;(3):CD004078.

    Google Scholar 

  24. Khrizman P, Niland JC, ter Veer A, et al. Postoperative adjuvant chemotherapy use in patients with stage II/III rectal cancer treated with neoadjuvant therapy: a national comprehensive cancer network analysis. J Clin Oncol. 2013;31:30–8.

    Article  PubMed  Google Scholar 

Download references

Disclosure

The authors declare no conflict of interest.

Author information

Authors and Affiliations

  1. Department of Surgery, College of Medicine, The Pennsylvania State University, Hershey, PA, USA

    Audrey S. Kulaylat MD, Christopher S. Hollenbeak PhD & David B. Stewart Sr MD, FACS, FASCRS

  2. Department of Public Health Sciences, College of Medicine, The Pennsylvania State University, Hershey, PA, USA

    Christopher S. Hollenbeak PhD

Authors
  1. Audrey S. Kulaylat MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Christopher S. Hollenbeak PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. David B. Stewart Sr MD, FACS, FASCRS
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to David B. Stewart Sr MD, FACS, FASCRS.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kulaylat, A.S., Hollenbeak, C.S. & Stewart, D.B. Adjuvant Chemotherapy Improves Overall Survival of Rectal Cancer Patients Treated with Neoadjuvant Chemoradiotherapy Regardless of Pathologic Nodal Status. Ann Surg Oncol 24, 1281–1288 (2017). https://doi.org/10.1245/s10434-016-5681-6

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-016-5681-6

Keywords

Search

Navigation